Erste Group downgraded Vertex Pharmaceuticals (VRTX) to Hold from Buy. The company’s ratio of inventories to sales has reached its highest level in the last 10 years, which is currently having a negative impact, the analyst tells investors in a research note. The firm says Vertex’s ratio of receivables to sales is also at a very high level.
Confident Investing Starts Here:
- Easily unpack a company's performance with TipRanks' new KPI Data for smart investment decisions
- Receive undervalued, market resilient stocks right to your inbox with TipRanks' Smart Value Newsletter
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on VRTX:
- Vertex Pharmaceuticals Launches $4 Billion Stock Buyback
- Vertex Pharmaceuticals: Strategic Positioning and Promising Growth Prospects Underpin Buy Rating
- Vertex Pharmaceuticals Holds Annual Shareholder Meeting
- Vertex Pharmaceuticals: Strong Growth and Promising Pipeline Justify Buy Rating
- Skechers, Shopify, Diamondback, Vertex, Turtle Beach: Trending by Analysts
Looking for a trading platform? Check out TipRanks' Best Online Brokers , and find the ideal broker for your trades.
Report an Issue